Poliglusam nanoparticles are potential therapeutic agents for the treatment of cancer. In particular, their efficacy has been reported as delivery systems in breast cancer. The aim of this study is to propose a new immunotherapeutic strategy, using Poliglusam nanoparticles as activators of the human immune response. Poliglusam nanoparticles were synthesized and characterized using both dynamic light scattering and electron microscopy. Whilst, their effectiveness in immune stimulation and detection of apoptosis was evaluated by cytokine and TUNEL assays. Finally, the cytokines pattern in splenocytes revealed an increase in IFN-γ production. The results of cytotoxicity on 4 T1 cells show an increase in the mortality rate with respect to the control cell line. The rate of apoptosis induced by Poliglusam nanoparticles on 4 T1 mouse breast cancer cell line is about 45% higher compared to MCF-7 human cells line, revealing the natural tendency of Poliglusam in increasing the production of IFN-γ in cancer cells. At the state-of-art of the knowledge, very few information have been achieved on the immunological effects of Poliglusam. This work is one of the first studies for the identification of non-functionalized Poliglusam nanoparticles impact on breast cancer. Thus, their immunotherapeutic effect, combined with an anticancer drug, can be employed as potential effective drug for eliminating breast cancer cells in the future.
Poliglusam Nanoparticles Breast cancer Immunotherapy and apoptosis
This is a preview of subscription content, log in to check access.
The authors specially thank the professor Majid Sadeghizadeh and his laboratory for their kind help at Tarbiat Modares University in Tehran and Shahid Beheshti University.
NS conceived the study. NS conducted the experiments and analyzed the results. NS and AV drafted the manuscript and made substantial contributions to the design of the study. NS and AV critically reviewed the manuscript and participated in data analysis. All the authors studied and approved the final manuscript.
Compliance with Ethical Standards
None to be declared.
The authors declare that there are no conflicts of interest.
Ajun W et al (2009) Preparation of aspirin and Probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym 75:566–574CrossRefGoogle Scholar
Anitha A et al (2011) Efficient water soluble O-carboxylmethyl chitosan Nanocarrier for the delivery of curcumin to Cancer cells. Carbohydr Polym 83:452–461CrossRefGoogle Scholar
Calvo P et al (1997) Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14:1431–1436CrossRefGoogle Scholar
Clarke MF et al (2006) Cancer stem cells--perspectives on current status and future directions: Aacr workshop on Cancer stem cells. Cancer Res 66:9339–9344CrossRefGoogle Scholar
Compton MM, Cidlowski JA (1986) Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology. 118:38–45CrossRefGoogle Scholar
Ebbinghaus C et al (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116:304–313CrossRefGoogle Scholar
García-Tuñón I et al (2007) Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 7:158CrossRefGoogle Scholar
Hosseinzadeh H et al (2012) Chitosan–Pluronic nanoparticles as Oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine 7:1851–1863CrossRefGoogle Scholar
Ikeda H et al (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109CrossRefGoogle Scholar
Illum L et al (1994) Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186–1189CrossRefGoogle Scholar
Kono T et al (1999) Cytotoxic activity of Pierisin, from the cabbage butterfly, Pieris Rapae, in various human Cancer cell lines. Cancer Lett 137:75–81CrossRefGoogle Scholar
Lee DY et al (2002) Chitosan and D-glucosamine induce expression of Th1 cytokine genes in porcine spleen cells. J Vet Med Sci 64:645–648CrossRefGoogle Scholar
Li GP et al (2009) Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol 6:45–50CrossRefGoogle Scholar
Me LT et al (2009) Cancer, chitosan and catalytic nucleic acids. J Pharm Pharmacol 61:3–12CrossRefGoogle Scholar
Moghaddam FA et al (2009) Preparation and in vitro evaluation of Mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine 5(2):208–15Google Scholar
Nunez C et al (2016) An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 97:34–50CrossRefGoogle Scholar
Peer D et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760CrossRefGoogle Scholar
Piccinini F et al (2017) Cell counting and viability assessment of 2D and 3D cell cultures: expected reliability of the trypan blue assay. Biol Proced Online 19:8CrossRefGoogle Scholar
Qi L et al (2004) Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 339:2693–2700CrossRefGoogle Scholar
Ruiz-Ruiz C et al (2000) Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673–5680Google Scholar
Sgadari C et al (1997) Mig, the Monokine induced by interferon-g, promotes tumor necrosis in vivo. Blood. 89:2635–2643Google Scholar
Stockler M et al (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast Cancer. Cancer Treat Rev 26:151–168CrossRefGoogle Scholar
Tang C et al (2007) Cancer stem cell: target for anti-Cancer therapy. FASEB J 21:3777–3785CrossRefGoogle Scholar
Windbichler GH et al (2000) Interferon-gamma in the first-line therapy of ovarian Cancer: a randomized phase iii trial. Br J Cancer 82:1138–1144CrossRefGoogle Scholar
Xu Y, Du Y (2003) Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 250:215–226CrossRefGoogle Scholar
Xu ZR et al (2004) Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res:2693–2700Google Scholar
Yousofi A et al (2012) Immunomodulatory effect of parsley (Petroselinum Crispum) essential oil on immune cells: mitogen-activated Splenocytes and peritoneal macrophages. Immunopharmacol Immunotoxicol 34:303–308CrossRefGoogle Scholar